메뉴 건너뛰기




Volumn 4, Issue 1 A, 2008, Pages 33-38

Monotherapy for partial epilepsy: Focus on levetiracetam

Author keywords

Antiepileptic drugs; Levetiracetam; Partial epilepsy

Indexed keywords

ETIRACETAM; FELBAMATE; PLACEBO;

EID: 41549125411     PISSN: 11766328     EISSN: None     Source Type: Journal    
DOI: 10.2147/ndt.s1655     Document Type: Article
Times cited : (42)

References (48)
  • 1
    • 13444269601 scopus 로고    scopus 로고
    • Clinical experience of levetiracetam monotherapy for adults with epilepsy: 1-year follow-up study
    • Alsaadi TM, Shatzel A, Marquez AV, et al. 2005. Clinical experience of levetiracetam monotherapy for adults with epilepsy: 1-year follow-up study. Seizure, 14:139-42.
    • (2005) Seizure , vol.14 , pp. 139-142
    • Alsaadi, T.M.1    Shatzel, A.2    Marquez, A.V.3
  • 2
    • 33847625508 scopus 로고    scopus 로고
    • Levetiracetam intravenous infusion as as alternative to oral dosing in patients with partial-onset seizures
    • Baulac M, Brodie MJ, Christian EE, et al. 2007. Levetiracetam intravenous infusion as as alternative to oral dosing in patients with partial-onset seizures. Epilepsia, 48:589-92.
    • (2007) Epilepsia , vol.48 , pp. 589-592
    • Baulac, M.1    Brodie, M.J.2    Christian, E.E.3
  • 3
    • 0033775210 scopus 로고    scopus 로고
    • Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: A multicenter, double-blind, responder-selected study evaluating monotherapy
    • Ben-Menachem E, Falter U. 2000. Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. Epilepsia, 41:1276-83.
    • (2000) Epilepsia , vol.41 , pp. 1276-1283
    • Ben-Menachem, E.1    Falter, U.2
  • 4
    • 33846850154 scopus 로고    scopus 로고
    • Comparison of levetiracetam and controlled release carbamazepine in newly diagnosed epilepsy
    • Brodie MJ, Perucca E., Ryvilin P., et al. 2007. Comparison of levetiracetam and controlled release carbamazepine in newly diagnosed epilepsy. Neurology, 68:402-8.
    • (2007) Neurology , vol.68 , pp. 402-408
    • Brodie, M.J.1    Perucca, E.2    Ryvilin, P.3
  • 5
    • 0033663648 scopus 로고    scopus 로고
    • Absence of pharmacokinetic drug interaction of levetiracetam with phenytoin in patients with epilepsy determined by new technique
    • Browne TR, Szabo GK, Leppik IE, et al. 2000. Absence of pharmacokinetic drug interaction of levetiracetam with phenytoin in patients with epilepsy determined by new technique. J Clin Pharmacol, 40:590-5.
    • (2000) J Clin Pharmacol , vol.40 , pp. 590-595
    • Browne, T.R.1    Szabo, G.K.2    Leppik, I.E.3
  • 6
    • 0033854805 scopus 로고    scopus 로고
    • Levetiracetam for partial seizures: Results of a double-blind, randomized clinical trial
    • Cereghino JJ, Biton V, Abou-Khalil B, et al. 2000. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology, 55:236-42.
    • (2000) Neurology , vol.55 , pp. 236-242
    • Cereghino, J.J.1    Biton, V.2    Abou-Khalil, B.3
  • 7
    • 0033756611 scopus 로고    scopus 로고
    • Levetiracetam: A review of its adjunctive use in the management of partial onset seizures
    • Dooley M, Plosker GL. 2000. Levetiracetam: a review of its adjunctive use in the management of partial onset seizures. Drugs, 60:871-93.
    • (2000) Drugs , vol.60 , pp. 871-893
    • Dooley, M.1    Plosker, G.L.2
  • 8
    • 13244272154 scopus 로고    scopus 로고
    • Rapid onset of action of levetiracetam in refractory epilepsy patients
    • French J, Arrigo C. 2005. Rapid onset of action of levetiracetam in refractory epilepsy patients. Epilepsia, 46:324-6.
    • (2005) Epilepsia , vol.46 , pp. 324-326
    • French, J.1    Arrigo, C.2
  • 9
    • 0034768383 scopus 로고    scopus 로고
    • A systematic review of the safety profile of levetiracetam: A new antiepileptic drug
    • French J, Edrich P, Cramer JA. 2001. A systematic review of the safety profile of levetiracetam: a new antiepileptic drug. Epilepsy Res, 47:77-90.
    • (2001) Epilepsy Res , vol.47 , pp. 77-90
    • French, J.1    Edrich, P.2    Cramer, J.A.3
  • 10
    • 11144356543 scopus 로고    scopus 로고
    • Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new onset epilepsy
    • French JA, Kanner AM, Bautista J, et al. 2004a. Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy. Neurology, 62:1252-60.
    • (2004) Neurology , vol.62 , pp. 1252-1260
    • French, J.A.1    Kanner, A.M.2    Bautista, J.3
  • 11
    • 11144353969 scopus 로고    scopus 로고
    • Efficacy and tolerability of the new antiepileptic drugs II: Treatment of refractory epilepsy
    • French JA, Kanner AM, Bautista J, et al. 2004b. Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy. Neurology, 62:1261-73.
    • (2004) Neurology , vol.62 , pp. 1261-1273
    • French, J.A.1    Kanner, A.M.2    Bautista, J.3
  • 12
    • 19444366567 scopus 로고    scopus 로고
    • Effect of levetiracetam on the pharmacokinetics of adjunctive antiepileptic drugs: A pooled analysis of data from randomized clinical trials
    • Gidal BE, Baltès E, Otoul C, et al. 2005. Effect of levetiracetam on the pharmacokinetics of adjunctive antiepileptic drugs: a pooled analysis of data from randomized clinical trials. Epilepsy Res, 64:1-11.
    • (2005) Epilepsy Res , vol.64 , pp. 1-11
    • Gidal, B.E.1    Baltès, E.2    Otoul, C.3
  • 13
    • 33745665605 scopus 로고    scopus 로고
    • Double-blind, randomized, placebo-controlled trial of adjunctive levetiracetain in pediatric partial seizures
    • Glauser TA, Ayala R, Elterman RD, et al. 2006. Double-blind, randomized, placebo-controlled trial of adjunctive levetiracetain in pediatric partial seizures. Neurology, 66:1654-60.
    • (2006) Neurology , vol.66 , pp. 1654-1660
    • Glauser, T.A.1    Ayala, R.2    Elterman, R.D.3
  • 14
    • 0036091188 scopus 로고    scopus 로고
    • Efficacy and safety of levetiracetam in children with partial seizures: An open-label trial
    • Glauser TA, Pellock JM, Bebin EM, et al. 2002. Efficacy and safety of levetiracetam in children with partial seizures: an open-label trial. Epilepsia, 43:518-24.
    • (2002) Epilepsia , vol.43 , pp. 518-524
    • Glauser, T.A.1    Pellock, J.M.2    Bebin, E.M.3
  • 15
    • 0028823233 scopus 로고
    • Effects of levetiracetam, a novel antiepileptic drug, on convulsant activity in two genetic rat models of epilepsy
    • Gower AJ, Hirsch E, Boehrer A, et al. 1995. Effects of levetiracetam, a novel antiepileptic drug, on convulsant activity in two genetic rat models of epilepsy. Epilepsy Res, 22:207-13.
    • (1995) Epilepsy Res , vol.22 , pp. 207-213
    • Gower, A.J.1    Hirsch, E.2    Boehrer, A.3
  • 16
    • 0026471112 scopus 로고
    • UCB L059, a novel anticonvulsant drug: Pharmacological profile in animals
    • Gower AJ, Noyer M, Verloes R, et al. 1992. UCB L059, a novel anticonvulsant drug: pharmacological profile in animals. Eur J Pharmacol, 222:193-203.
    • (1992) Eur J Pharmacol , vol.222 , pp. 193-203
    • Gower, A.J.1    Noyer, M.2    Verloes, R.3
  • 17
    • 0034878396 scopus 로고    scopus 로고
    • Safety profile of levetiracetam
    • Harden C. 2001. Safety profile of levetiracetam. Epilepsia, 42(Suppl 4):36-9.
    • (2001) Epilepsia , vol.42 , Issue.SUPPL. 4 , pp. 36-39
    • Harden, C.1
  • 18
    • 0035169113 scopus 로고    scopus 로고
    • Levetiracetam: A novel antiepileptic drug
    • Hovinga CA. 2001. Levetiracetam: a novel antiepileptic drug. Pharmacotherapy, 21:1375-88.
    • (2001) Pharmacotherapy , vol.21 , pp. 1375-1388
    • Hovinga, C.A.1
  • 19
    • 0030297525 scopus 로고    scopus 로고
    • Photosensitive epilepsy: A model to study the effects of antiepileptic drugs. Evaluation of the piracetam analogue, levetiracetam
    • Kasteleijn-Nolst Trenité DGA, Marescaux C, Stodieck S, et al. 1996. Photosensitive epilepsy: a model to study the effects of antiepileptic drugs. Evaluation of the piracetam analogue, levetiracetam. Epilepsy Res, 25:225-30.
    • (1996) Epilepsy Res , vol.25 , pp. 225-230
    • Kasteleijn-Nolst Trenité, D.G.A.1    Marescaux, C.2    Stodieck, S.3
  • 20
    • 41549165909 scopus 로고    scopus 로고
    • Summary of product characteristics. Brussels, Belgium: UCB SA
    • 250 mg, 500 mg, 1000 mg, June
    • Keppre™ (250 mg, 500 mg, 1000 mg). 2000b. Summary of product characteristics. Brussels, Belgium: UCB SA. June 2000.
    • (2000)
    • Keppre™1
  • 21
    • 41549162651 scopus 로고    scopus 로고
    • Keppra™ levetiracetam 250, 500, 750 mg tablets. 2000a. Prescribing information. Brussels, Belgium: UCB Pharma.
    • Keppra™ levetiracetam 250, 500, 750 mg tablets. 2000a. Prescribing information. Brussels, Belgium: UCB Pharma.
  • 22
    • 0032563178 scopus 로고    scopus 로고
    • Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy
    • Klitgaard R, Matagne A, Gobert J, et al. 1998. Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. Eur J Pharmacol, 353:191-206.
    • (1998) Eur J Pharmacol , vol.353 , pp. 191-206
    • Klitgaard, R.1    Matagne, A.2    Gobert, J.3
  • 23
    • 0034864144 scopus 로고    scopus 로고
    • Levetiracetam: The preclinical profile of a new class of antiepileptic drugs?
    • Klitgaard H. 2001, Levetiracetam: the preclinical profile of a new class of antiepileptic drugs? Epilepsia, 42(Suppl 4):13-18.
    • (2001) Epilepsia , vol.42 , Issue.SUPPL. 4 , pp. 13-18
    • Klitgaard, H.1
  • 24
    • 0035673064 scopus 로고    scopus 로고
    • Levetiracetam psychosis in children with epilepsy
    • Kossoff EH, Bergey GK, Freeman JM, et al. 2001. Levetiracetam psychosis in children with epilepsy. Epilepsia, 42:1611-3.
    • (2001) Epilepsia , vol.42 , pp. 1611-1613
    • Kossoff, E.H.1    Bergey, G.K.2    Freeman, J.M.3
  • 25
    • 0035954353 scopus 로고    scopus 로고
    • Long-term continuation of levetiracetam in patients with refractory epilepsy
    • Krakow D, Walker W, Otoul C, et al. 2001. Long-term continuation of levetiracetam in patients with refractory epilepsy. Neurology, 56:1772-4.
    • (2001) Neurology , vol.56 , pp. 1772-1774
    • Krakow, D.1    Walker, W.2    Otoul, C.3
  • 26
    • 33645022604 scopus 로고    scopus 로고
    • Levetiracetam in patients with generalised epilepsy and myoclonic seizures: An open label study
    • Labate A, Colosimo E, Gambardella A, et al. 2006. Levetiracetam in patients with generalised epilepsy and myoclonic seizures: an open label study. Seizure, 15:214-8.
    • (2006) Seizure , vol.15 , pp. 214-218
    • Labate, A.1    Colosimo, E.2    Gambardella, A.3
  • 27
    • 0347994963 scopus 로고    scopus 로고
    • Levetiracetam and partial seizure subtypes: Pooled data from three randomized, placebo-controlled trials
    • Leppik IE, Biton V, Sander JW, et al. 2003. Levetiracetam and partial seizure subtypes: pooled data from three randomized, placebo-controlled trials. Epilepsia, 44:1585-7.
    • (2003) Epilepsia , vol.44 , pp. 1585-1587
    • Leppik, I.E.1    Biton, V.2    Sander, J.W.3
  • 28
    • 0034900762 scopus 로고    scopus 로고
    • Repeated administration of the novel antiepileptic agent levetiracetam does not alter digoxin pharmacokinetics and pharmacodynamics in healthy volunteers
    • Levy RH, Ragueneau-Majlessi I, Baltes E. 2001. Repeated administration of the novel antiepileptic agent levetiracetam does not alter digoxin pharmacokinetics and pharmacodynamics in healthy volunteers. Epilepsy Res, 46:93-9.
    • (2001) Epilepsy Res , vol.46 , pp. 93-99
    • Levy, R.H.1    Ragueneau-Majlessi, I.2    Baltes, E.3
  • 29
    • 0031908063 scopus 로고    scopus 로고
    • Antiepileptogenic effects of the novel anticonvulsant levetiracetam. (ucb L059) in the kindling model of temporal lobe epilepsy
    • Löscher W, Hönack D, Rundfeldt C. 1998. Antiepileptogenic effects of the novel anticonvulsant levetiracetam. (ucb L059) in the kindling model of temporal lobe epilepsy. J Pharmacol Exp Ther, 284:474-9.
    • (1998) J Pharmacol Exp Ther , vol.284 , pp. 474-479
    • Löscher, W.1    Hönack, D.2    Rundfeldt, C.3
  • 30
    • 0027410987 scopus 로고
    • Profile of ucb L059, a novel anticonvulsant drug, in models of partial and generalised epilepsy in mice and rats
    • Löscher W, Hönack D. 1993. Profile of ucb L059, a novel anticonvulsant drug, in models of partial and generalised epilepsy in mice and rats. Eur J Pharmacol, 232:147-58.
    • (1993) Eur J Pharmacol , vol.232 , pp. 147-158
    • Löscher, W.1    Hönack, D.2
  • 31
    • 34247096547 scopus 로고    scopus 로고
    • Levetiracetam and felbamate interact both pharmacodynamically and pharmacokinetically: An isobolographic analysis in the mouse maximal electroshock model
    • Luszczki JJ, Andres-Mach MM, Ratnaraj N, et al. 2007. Levetiracetam and felbamate interact both pharmacodynamically and pharmacokinetically: an isobolographic analysis in the mouse maximal electroshock model. Epilepsia, 48:806-15.
    • (2007) Epilepsia , vol.48 , pp. 806-815
    • Luszczki, J.J.1    Andres-Mach, M.M.2    Ratnaraj, N.3
  • 32
    • 0002260079 scopus 로고    scopus 로고
    • Effect of levetiracetam on voltage-gated, potassium channels: A novel anti-epileptic mechanism?
    • Madeja M, Margineanou D, Klitgaard H. 2001. Effect of levetiracetam on voltage-gated, potassium channels: a novel anti-epileptic mechanism? Epilepsia, 42(suppl 2):19.
    • (2001) Epilepsia , vol.42 , Issue.SUPPL. 2 , pp. 19
    • Madeja, M.1    Margineanou, D.2    Klitgaard, H.3
  • 33
    • 0042836602 scopus 로고    scopus 로고
    • Psychiatric adverse events during levetiracetam therapy
    • Mula M, Trimble MR, Yuen A, et al. 2003. Psychiatric adverse events during levetiracetam therapy. Neurology, 61:704-6.
    • (2003) Neurology , vol.61 , pp. 704-706
    • Mula, M.1    Trimble, M.R.2    Yuen, A.3
  • 35
    • 0032963256 scopus 로고    scopus 로고
    • In vitro evaluation of potential drug interactions with levetiracetam, a new antiepileptic agent
    • Nicolas JM, Collart P, Germ B, et al. 1999. In vitro evaluation of potential drug interactions with levetiracetam, a new antiepileptic agent. Drug Metab Dispos, 27:250-4.
    • (1999) Drug Metab Dispos , vol.27 , pp. 250-254
    • Nicolas, J.M.1    Collart, P.2    Germ, B.3
  • 37
    • 0028825031 scopus 로고
    • The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes
    • Noyer M, Gillard M, Matagne A, et al. 1995. The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes. Eur J Pharmacol, 286:137-46.
    • (1995) Eur J Pharmacol , vol.286 , pp. 137-146
    • Noyer, M.1    Gillard, M.2    Matagne, A.3
  • 38
    • 0035675738 scopus 로고    scopus 로고
    • Pharmacokinetic study of levetiracetam in children
    • Pellock JM, Glauser TA, Bebin EM, et al. 2001. Pharmacokinetic study of levetiracetam in children. Epilepsia, 42:1574-9.
    • (2001) Epilepsia , vol.42 , pp. 1574-1579
    • Pellock, J.M.1    Glauser, T.A.2    Bebin, E.M.3
  • 39
    • 0034864245 scopus 로고    scopus 로고
    • Pharmacokinetics of levetiracetain
    • Radtke RA. 2001. Pharmacokinetics of levetiracetain. Epilepsia, 42(Suppl 4):24-7.
    • (2001) Epilepsia , vol.42 , Issue.SUPPL. 4 , pp. 24-27
    • Radtke, R.A.1
  • 40
    • 33746115639 scopus 로고    scopus 로고
    • Levetiracetam intravenous infusion: A randomized, placebo-controlled safety and pharmacokinetic study
    • Ramael S, Daoust A, Otoul C, et al. 2006b. Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study. Epilepsia. 47:1128-35.
    • (2006) Epilepsia , vol.47 , pp. 1128-1135
    • Ramael, S.1    Daoust, A.2    Otoul, C.3
  • 41
    • 33745974941 scopus 로고    scopus 로고
    • Single dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects
    • Ramael S, De Smedt F, Toublanc N, et al. 2006. Single dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects. Clin Ther, 28:734-44.
    • (2006) Clin Ther , vol.28 , pp. 734-744
    • Ramael, S.1    De Smedt, F.2    Toublanc, N.3
  • 42
    • 33745974941 scopus 로고    scopus 로고
    • Single-dose bioavalability of levetiravetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects
    • Ramael S, De Smedt F, Toublanc N, et al. 2006a. Single-dose bioavalability of levetiravetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects. Clinical Therapeutics, 28:734-44.
    • (2006) Clinical Therapeutics , vol.28 , pp. 734-744
    • Ramael, S.1    De Smedt, F.2    Toublanc, N.3
  • 43
    • 0002349243 scopus 로고    scopus 로고
    • Levetiracetam: Novel modulation of ionotropic inhibitory receptors
    • Rigo J-K Nguyen L, Belachew S, et al. 2000. Levetiracetam: novel modulation of ionotropic inhibitory receptors. Epilepsia, 41(Suppl 7):35.
    • (2000) Epilepsia , vol.41 , Issue.SUPPL. 7 , pp. 35
    • Rigo, J.-K.1    Nguyen, L.2    Belachew, S.3
  • 44
    • 0033811027 scopus 로고    scopus 로고
    • Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures
    • Shorvon SD, Lowenthal A, Janz D, et al. 2000. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. Epilepsia, 41:1179-86.
    • (2000) Epilepsia , vol.41 , pp. 1179-1186
    • Shorvon, S.D.1    Lowenthal, A.2    Janz, D.3
  • 46
    • 0035655764 scopus 로고    scopus 로고
    • Pyrrolidone derivatives
    • Shorvon SD. 2001. Pyrrolidone derivatives. Lancet, 200:1885-92.
    • (2001) Lancet , vol.200 , pp. 1885-1892
    • Shorvon, S.D.1
  • 47
    • 33645019934 scopus 로고    scopus 로고
    • Efficacy and safety of levetiracetam (up to 2000 mg/day) in Taiwanese patients with refractory partial seizures: A multicenter, randomized, double-blind, placebo-controlled study
    • Tsai JJ, Yen DJ, Hsih MS, et al. 2006. Efficacy and safety of levetiracetam (up to 2000 mg/day) in Taiwanese patients with refractory partial seizures: a multicenter, randomized, double-blind, placebo-controlled study. Epilepsia, 47:72-81.
    • (2006) Epilepsia , vol.47 , pp. 72-81
    • Tsai, J.J.1    Yen, D.J.2    Hsih, M.S.3
  • 48
    • 0034883899 scopus 로고    scopus 로고
    • Levetiracetam does not modulate neuronal voltage-gated Na+ and T-type Ca2+ currents
    • Zona C, Niespodziany I, Marchetti C, et al. 2001. Levetiracetam does not modulate neuronal voltage-gated Na+ and T-type Ca2+ currents. Seizure, 10:279-86.
    • (2001) Seizure , vol.10 , pp. 279-286
    • Zona, C.1    Niespodziany, I.2    Marchetti, C.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.